NICE backs Opdivo for classical Hodgkin lymphoma

2nd June 2017 Uncategorised 0

Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.

More: NICE backs Opdivo for classical Hodgkin lymphoma
Source: News